AU1735001A - Cyclodextrin-containing pharmaceutical composition - Google Patents

Cyclodextrin-containing pharmaceutical composition

Info

Publication number
AU1735001A
AU1735001A AU17350/01A AU1735001A AU1735001A AU 1735001 A AU1735001 A AU 1735001A AU 17350/01 A AU17350/01 A AU 17350/01A AU 1735001 A AU1735001 A AU 1735001A AU 1735001 A AU1735001 A AU 1735001A
Authority
AU
Australia
Prior art keywords
cyclodextrin
pharmaceutical composition
containing pharmaceutical
composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17350/01A
Inventor
Jun Inoue
Toshihiro Ishiguro
Masayuki Nakamura
Masazumi Yamaguchi
Yukuo Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd, Takeda Chemical Industries Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of AU1735001A publication Critical patent/AU1735001A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU17350/01A 1999-12-10 2000-12-08 Cyclodextrin-containing pharmaceutical composition Abandoned AU1735001A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP11/352413 1999-12-10
JP35241399 1999-12-10
JP2000035645 2000-02-08
JP2000-35645 2000-02-08
JP2000-365690 2000-11-30
JP2000365690 2000-11-30
PCT/JP2000/008700 WO2001041757A1 (en) 1999-12-10 2000-12-08 Cyclodextrin-containing pharmaceutical composition

Publications (1)

Publication Number Publication Date
AU1735001A true AU1735001A (en) 2001-06-18

Family

ID=27341415

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17350/01A Abandoned AU1735001A (en) 1999-12-10 2000-12-08 Cyclodextrin-containing pharmaceutical composition

Country Status (2)

Country Link
AU (1) AU1735001A (en)
WO (1) WO2001041757A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1334718A4 (en) * 2000-10-26 2007-07-18 Senju Pharma Co Drug composition comprising dipeptidyl aldehyde derivative
JP4564920B2 (en) * 2003-04-18 2010-10-20 株式会社最先端医学研究所 Disease treatment agent applied to the eye
JP2008520546A (en) * 2004-09-21 2008-06-19 アドバンスト メディカル オプティクス， インコーポレーテッド Viscoelastic solution or gel formulation and method of treating a body part using the same
WO2006040839A1 (en) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute Eye drops and kit for treatment of eye disease
PL1888548T3 (en) 2005-05-26 2013-01-31 Neuron Systems Inc Quinoline derivative for the treatment of retinal diseases
CA2782015C (en) * 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
JP2013245213A (en) * 2012-05-29 2013-12-09 Jx Nippon Oil & Energy Corp Clathrate of eriobotrya japonica leaf culture extract and cyclodextrin
AU2013361314A1 (en) 2012-12-20 2015-07-02 Aldeyra Therapeutics, Inc. Peri-carbinols
KR102435676B1 (en) 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. Toxic aldehyde related diseases and treatment
EP2948436A4 (en) 2013-01-25 2016-07-13 Aldeyra Therapeutics Inc Novel traps in the treatment of macular degeneration
BR112018003250A2 (en) 2015-08-21 2018-09-25 Aldeyra Therapeutics Inc deuterated compounds and uses thereof
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3077362A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7505786B2 (en) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド Formulations for treating dry eye disease
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN114557970B (en) * 2022-03-17 2023-03-31 浙江长典药物技术开发有限公司 Mitomycin freeze-dried powder for eyes and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196427T1 (en) * 1993-12-06 2000-10-15 Takeda Chemical Industries Ltd COMPOSITION WITH IMPROVED WATER SOLUBILITY, CONTAINING A WATER-INSOLUBLE OR POORLY WATER-INSOLUBLE COMPOUND
ATE230275T1 (en) * 1995-10-25 2003-01-15 Senju Pharma Co ANGIOGENSIS INHIBITOR
JPH09235302A (en) * 1996-03-01 1997-09-09 Takeda Chem Ind Ltd Branched cyclodextrincarboxylic acid ester and its production

Also Published As

Publication number Publication date
WO2001041757A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AU781269C (en) Pharmaceutical compositions
AU1071301A (en) Pharmaceutical compounds
AU3192700A (en) Medicinal compositions
PL351387A1 (en) Pharmaceutical composition
AU1735001A (en) Cyclodextrin-containing pharmaceutical composition
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU3556400A (en) Pharmaceutical compositions
AU4318000A (en) Agarobiose-containing composition
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2005300A (en) Medicinal compositions
AU1887401A (en) Medicinal composition
AU1290501A (en) Composition
AU4328800A (en) Pharmaceutical formulation
AU4304400A (en) Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
AU5460800A (en) Pharmaceutical transdermal compositions
AU6460400A (en) Pharmaceutical compositions
AU2001273919A1 (en) Pharmaceutical compositions
AU6460200A (en) Pharmaceutical compositions
AU5722900A (en) Pharmaceutical compounds
AUPP332898A0 (en) Pharmaceutical composition
AU4085201A (en) Pharmaceutical composition
AU6460300A (en) Pharmaceutical compositions
AU6460100A (en) Pharmaceutical compositions
AU4543500A (en) Pharmaceutical compositions and uses

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase